Today, we're zooming in on key cases decided this past year and unpacking their broader implications for the pharmaceutical industry. We’ll look at decisions that refined safe harbor provisions, imposed stricter scrutiny on certain patents, tackled Orange Book listings, and much more. 

And before we close, we’ll share some insights into what the industry may encounter in 2025, so stick around to the end to hear what to expect in the coming year. 

Read the full article
2024 Hatch-Waxman Year in Review

About the authors
Ben Bourke
Alexander P. Wharton